Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.55 CAD
Change Today 0.00 / 0.00%
Volume 0.0
RVX On Other Exchanges
Symbol
Exchange
Berlin
Toronto
OTC US
As of 3:58 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

resverlogix corp (RVX) Snapshot

Open
C$1.65
Previous Close
C$1.55
Day High
C$1.67
Day Low
C$1.54
52 Week High
03/13/15 - C$1.93
52 Week Low
12/11/14 - C$0.41
Market Cap
132.8M
Average Volume 10 Days
329.1K
EPS TTM
C$0.24
Shares Outstanding
85.7M
EX-Date
--
P/E TM
5.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for RESVERLOGIX CORP (RVX)

Related News

No related news articles were found.

resverlogix corp (RVX) Related Businessweek News

No Related Businessweek News Found

resverlogix corp (RVX) Details

Resverlogix Corp., a clinical stage biotechnology company, develops small molecules that selectively inhibit Bromodomain and ExtraTerminal domain proteins for high risk vascular diseases. The company is developing RVX-208, a small molecule that is in clinical trials for the treatment of atherosclerosis and other chronic diseases, such as diabetes mellitus and Alzheimer's disease. Resverlogix Corp. is headquartered in Calgary, Canada.

19 Employees
Last Reported Date: 07/29/14

resverlogix corp (RVX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$404.6K
Chief Financial Officer
Total Annual Compensation: C$241.7K
Senior Vice President of Medical Affairs
Total Annual Compensation: C$183.8K
Compensation as of Fiscal Year 2014.

resverlogix corp (RVX) Key Developments

Resverlogix Corp. Presents New Data on RVX-208 at the American College of Cardiology 64th Annual Scientific Session &Expo (ACC.15)

Resverlogix Corp. announced that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix presented new data on RVX-208 at the p ACC.15 Scientific Sessions in San Diego, CA. RVX-208 is an orally active small molecule that interacts selectively with the second ligand binding domain present in BET proteins. RVX-208 inhibits these proteins from binding to the natural ligand acetylated lysine, found in the tail of histone proteins. This interaction modulates the structure of chromatin which in turn leads to altered activity of selected genes. This is the epigenetic mechanism by which RVX-208 increases production of ApoA-I the dominant protein in high density lipoproteins (HDL). Recent analysis of pooled data from Phase 2b clinical trials SUSTAIN and ASSURE (n=499 over 6 months) revealed a marked 55% (p=0.02) relative risk reduction (RRR) in major adverse cardiac events (MACE) for the entire population with a more pronounced effect of -77% RRR (p=0.01) in those with diabetes mellitus (DM). Biomarker analysis from the SUSTAIN and ASSURE trials revealed significant changes between RVX-208 vs. placebo (change, p value) in: serum alkaline phosphatase (-6 U/L, (0.0001), HDL-c (+3 mg/dL, (0.001), ApoA-I (+7.5 mg/dL, (0.01), large HDL (+0.7 umol/L, (0.05), HDL size (+0.1, (0.05), and total HDL particles (+1.8 umol/L, (0.1). While these findings were evident in all patients, two groups appeared to benefit more from RVX-208 were those with DM or chronic kidney disease (CKD). In those with DM (n=192) given RVX-208, glucose was unchanged versus a non-significant (p(0.1) rise of +0.7 mmol/L in placebo patients. In those with DM (n=119) and low HDL (40 mg/dL, RVX-208 reduced glucose significantly (p(0.01) by -0.3 mmol/L while in placebo the glucose increased +0.9 mmol/L. In CKD subjects (n=48) with mild to moderate renal failure (eGFR (60 mL/min/1.73mto a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.

Resverlogix Corp. Completes Collaborative Research Program with Emerald Logic

Resverlogix Corp. announced that it has completed a collaborative research program with Emerald Logic. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE. The objective of this collaborative program was to develop quantitative models and identify variables that contribute to drug response, and the incidence of major adverse cardiac events (MACE). The complete dataset, containing approximately 650,000 data points, was analyzed using Emerald Logic's FACET software. This unique approach combines medical history, epidemiology, demographics, patient vital signs, and clinical lab measures in order to identify explanatory factors for efficacy and adverse events and to produce discriminatory models without bias or guidance. The collaboration generated multiple proprietary models and deduced both binary and continuous variables, previously unidentified, that contribute to drug efficacy, adverse events and most importantly to the observed reduction in MACE incidence in response to treatment with RVX-208. The Company plans to file new intellectual property surrounding these variables and algorithms and intends to integrate and assess them in upcoming clinical trials for the purpose of patient enrichment and safety monitoring. RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET-Bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes either on or off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with disease such as cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with diabetes mellitus and low HDL.

Resverlogix Corp. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:45 AM

Resverlogix Corp. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:45 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVX:CN C$1.55 CAD 0.00

RVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVX.
View Industry Companies
 

Industry Analysis

RVX

Industry Average

Valuation RVX Industry Range
Price/Earnings 56.3x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 57.3x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESVERLOGIX CORP, please visit www.resverlogix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.